Thread Tools Display Modes
Prev Previous Post   Next Post Next
Old 12-15-2010, 10:28 AM #23
Chilax Chilax is offline
New Member
 
Join Date: Dec 2010
Location: NJ
Posts: 3
10 yr Member
Chilax Chilax is offline
New Member
 
Join Date: Dec 2010
Location: NJ
Posts: 3
10 yr Member
Default

Thanks for the insightful information on Gilenya. I was dx'd in October and have opted for Gilenya over Tysabri. I have been trying to find any information on long-term users such as those in the clinical trials that have continued use so your post has been very helpful. Once I start Gilenya (early January) I will post my experience.

Thanks again.

Al
Quote:
Originally Posted by Natalie8 View Post
I saw my neuro today to talk about Gilenya. He has been following the data of the 300 or so people who have been on the drug for 6 years and the couple of thousand who have been on it for 3 years. He said it doesn't look like UTI's are a big problem. But people get lots of respiratory infections. Also herpes infections are a problem but he is not worried because as he said "we have treatments for that but not for PML which you get on Tysabri". He said more people seem to be getting viral infections rather than bacterial infections. It has a different mechanism of immunosuppression than Tysabri.

He said only people with asthma or other chronic respiratory issues should avoid the drug. For those with healthy lungs he saw no evidence of damaging pulmonary effect during or after going off the drug. He also told me the data did NOT show any cardiotoxicity (that's different than the initial slowed heartrate). That doesn't mean it can't happen 10 years out...but we at least have some people 6 years out.
There were 6 cases of macular edema. In 5 it went away after the drug was stopped. One person was left with vision problems afterward but that patient was on the higher dose that is not being prescribed anymore. He said that most eye problems developed in the first 4 months.
He recommended dermatology checks regularly.
He likes what he has seen so far. Apparently my clinic is setting up 5-6 people to wait out the 6 hour first dose together--I guess it's similar to the infusion clinic when you get Tysabri. So you better hope you like the people you are stuck with for 6 hours!!! The funny thing is he is really a Tysabri and Avonex guy--not a shill for Novartis at all. He left it up to me to decide.
If I remember anything else he said I will let you know.
By the way he does not like cladribine because of high cancer risks and everyone in the clinic has a pool going about whether the FDA will ultimately reject it. Everyone says yes.
Chilax is offline   Reply With QuoteReply With Quote
"Thanks for this!" says:
barb02 (12-15-2010), dmplaura (12-15-2010), ewizabeth (12-21-2010), Natalie8 (12-15-2010)
 


Posting Rules
You may not post new threads
You may not post replies
You may not post attachments
You may not edit your posts

BB code is On
Smilies are On
[IMG] code is On
HTML code is Off


Similar Threads
Thread Thread Starter Forum Replies Last Post
What I learned about fingolimod today Natalie8 Multiple Sclerosis 7 08-13-2010 07:04 PM
new information on Gilenia (Fingolimod) Natalie8 Multiple Sclerosis 7 06-18-2010 11:24 AM
Novartis had changed the name of Fingolimod to Gilenia (aka FTY720). Lady Multiple Sclerosis 0 04-28-2010 10:58 PM
FTY720/Fingolimod Riverwild Multiple Sclerosis 15 06-16-2008 03:40 PM
Fingolimod/FTY720 Research from ECTRIMS xo++ Multiple Sclerosis 6 09-30-2006 01:21 AM


All times are GMT -5. The time now is 03:18 PM.


Powered by vBulletin • Copyright ©2000 - 2025, Jelsoft Enterprises Ltd.

vBulletin Optimisation provided by vB Optimise (Lite) - vBulletin Mods & Addons Copyright © 2025 DragonByte Technologies Ltd.
 

NeuroTalk Forums

Helping support those with neurological and related conditions.

 

The material on this site is for informational purposes only,
and is not a substitute for medical advice, diagnosis or treatment
provided by a qualified health care provider.


Always consult your doctor before trying anything you read here.